Similarly, in NSCLC patients with a high MET GCN or high levels of overexpression of MET, treatment with capmatinib has prolonged PFS and led to a reduced tumor burden and higher overall response rates compared to cohorts with lower grades of overexpression or amplification. The gene discussed is MET; the disease is non-small cell lung carcinoma.